APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting ESAs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting ESAs Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchLong-acting ESAs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting ESAs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Long-acting ESAs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting ESAs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting ESAs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting ESAs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting ESAs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting ESAs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting ESAs market include Amgen, Cipla, CKD Pharma, Dr. Reddy's Laboratories, Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Torrent Pharmaceuticals and Hansoh Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting ESAs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting ESAs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting ESAs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting ESAs market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting ESAs Segment by Company

Amgen

Cipla

CKD Pharma

Dr. Reddy's Laboratories

Kissei Pharmaceutical

Kyowa Hakko Kirin

Sanwa Kagaku Kenkyusho

Torrent Pharmaceuticals

Hansoh Pharma

Roche

Kyowa Kirin

Long-acting ESAs Segment by Type

Pegmolesatide

Methoxy Polyethylene Glycol-Epoetin Beta

Darbepoetin Alfa

Long-acting ESAs Segment by Application

Renal Anemia

Cancer

Other

Long-acting ESAs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting ESAs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting ESAs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting ESAs significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting ESAs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting ESAs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting ESAs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting ESAs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting ESAs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting ESAs industry.

Chapter 3: Detailed analysis of Long-acting ESAs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting ESAs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting ESAs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting ESAs Industry Trends Table 2. Long-acting ESAs Industry Drivers Table 3. Long-acting ESAs Industry Opportunities and Challenges Table 4. Long-acting ESAs Industry Restraints Table 5. Global Long-acting ESAs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting ESAs Revenue Share by Company (2021-2026) Table 7. Global Long-acting ESAs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Long-acting ESAs Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting ESAs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Long-acting ESAs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting ESAs Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting ESAs Company, Product Type & Application Table 13. Global Long-acting ESAs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting ESAs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pegmolesatide Table 18. Significant Companies of Methoxy Polyethylene Glycol-Epoetin Beta Table 19. Significant Companies of Darbepoetin Alfa Table 20. Global Long-acting ESAs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Long-acting ESAs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Long-acting ESAs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Long-acting ESAs Sales Volume Share by Type (2021-2026) Table 24. Global Long-acting ESAs Sales Volume Share by Type (2027-2032) Table 25. Global Long-acting ESAs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting ESAs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Long-acting ESAs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Long-acting ESAs Sales Value Share by Type (2021-2026) Table 29. Global Long-acting ESAs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Renal Anemia Table 31. Significant Companies of Cancer Table 32. Significant Companies of Other Table 33. Global Long-acting ESAs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Long-acting ESAs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Long-acting ESAs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Long-acting ESAs Sales Volume Share by Application (2021-2026) Table 37. Global Long-acting ESAs Sales Volume Share by Application (2027-2032) Table 38. Global Long-acting ESAs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Long-acting ESAs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Long-acting ESAs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Long-acting ESAs Sales Value Share by Application (2021-2026) Table 42. Global Long-acting ESAs Sales Value Share by Application (2027-2032) Table 43. Global Long-acting ESAs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Long-acting ESAs Sales by Region (2021-2026) & (K Units) Table 45. Global Long-acting ESAs Sales Market Share by Region (2021-2026) Table 46. Global Long-acting ESAs Sales by Region (2027-2032) & (K Units) Table 47. Global Long-acting ESAs Sales Market Share by Region (2027-2032) Table 48. Global Long-acting ESAs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Long-acting ESAs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Long-acting ESAs Sales Value Share by Region (2021-2026) Table 51. Global Long-acting ESAs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Long-acting ESAs Sales Value Share by Region (2027-2032) Table 53. Global Long-acting ESAs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Long-acting ESAs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Long-acting ESAs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 58. Global Long-acting ESAs Sales Market Share by Country (2021-2026) Table 59. Global Long-acting ESAs Sales by Country (2027-2032) & (K Units) Table 60. Global Long-acting ESAs Sales Market Share by Country (2027-2032) Table 61. Global Long-acting ESAs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Long-acting ESAs Sales Value Market Share by Country (2021-2026) Table 63. Global Long-acting ESAs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Long-acting ESAs Sales Value Market Share by Country (2027-2032) Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Amgen Long-acting ESAs Product Portfolio Table 69. Amgen Recent Development Table 70. Cipla Company Information Table 71. Cipla Business Overview Table 72. Cipla Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Cipla Long-acting ESAs Product Portfolio Table 74. Cipla Recent Development Table 75. CKD Pharma Company Information Table 76. CKD Pharma Business Overview Table 77. CKD Pharma Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. CKD Pharma Long-acting ESAs Product Portfolio Table 79. CKD Pharma Recent Development Table 80. Dr. Reddy's Laboratories Company Information Table 81. Dr. Reddy's Laboratories Business Overview Table 82. Dr. Reddy's Laboratories Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio Table 84. Dr. Reddy's Laboratories Recent Development Table 85. Kissei Pharmaceutical Company Information Table 86. Kissei Pharmaceutical Business Overview Table 87. Kissei Pharmaceutical Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Kissei Pharmaceutical Long-acting ESAs Product Portfolio Table 89. Kissei Pharmaceutical Recent Development Table 90. Kyowa Hakko Kirin Company Information Table 91. Kyowa Hakko Kirin Business Overview Table 92. Kyowa Hakko Kirin Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Kyowa Hakko Kirin Long-acting ESAs Product Portfolio Table 94. Kyowa Hakko Kirin Recent Development Table 95. Sanwa Kagaku Kenkyusho Company Information Table 96. Sanwa Kagaku Kenkyusho Business Overview Table 97. Sanwa Kagaku Kenkyusho Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio Table 99. Sanwa Kagaku Kenkyusho Recent Development Table 100. Torrent Pharmaceuticals Company Information Table 101. Torrent Pharmaceuticals Business Overview Table 102. Torrent Pharmaceuticals Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Torrent Pharmaceuticals Long-acting ESAs Product Portfolio Table 104. Torrent Pharmaceuticals Recent Development Table 105. Hansoh Pharma Company Information Table 106. Hansoh Pharma Business Overview Table 107. Hansoh Pharma Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Hansoh Pharma Long-acting ESAs Product Portfolio Table 109. Hansoh Pharma Recent Development Table 110. Roche Company Information Table 111. Roche Business Overview Table 112. Roche Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Roche Long-acting ESAs Product Portfolio Table 114. Roche Recent Development Table 115. Kyowa Kirin Company Information Table 116. Kyowa Kirin Business Overview Table 117. Kyowa Kirin Long-acting ESAs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Kyowa Kirin Long-acting ESAs Product Portfolio Table 119. Kyowa Kirin Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Long-acting ESAs Distributors List Table 123. Long-acting ESAs Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Long-acting ESAs Product Image Figure 2. Global Long-acting ESAs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting ESAs Sales (2021-2032) & (K Units) Figure 5. Global Long-acting ESAs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Long-acting ESAs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pegmolesatide Image Figure 10. Methoxy Polyethylene Glycol-Epoetin Beta Image Figure 11. Darbepoetin Alfa Image Figure 12. Global Long-acting ESAs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Long-acting ESAs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Long-acting ESAs Sales Volume Share by Type (2021-2032) Figure 15. Global Long-acting ESAs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long-acting ESAs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long-acting ESAs Sales Value Share by Type (2021-2032) Figure 18. Renal Anemia Image Figure 19. Cancer Image Figure 20. Other Image Figure 21. Global Long-acting ESAs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Long-acting ESAs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Long-acting ESAs Sales Volume Share by Application (2021-2032) Figure 24. Global Long-acting ESAs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Long-acting ESAs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Long-acting ESAs Sales Value Share by Application (2021-2032) Figure 27. Global Long-acting ESAs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Long-acting ESAs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Long-acting ESAs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Long-acting ESAs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Long-acting ESAs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Long-acting ESAs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Long-acting ESAs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Long-acting ESAs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Long-acting ESAs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Long-acting ESAs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Long-acting ESAs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Long-acting ESAs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Long-acting ESAs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Long-acting ESAs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Long-acting ESAs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Pegmolesatide
  • Methoxy Polyethylene Glycol-Epoetin Beta
  • Darbepoetin Alfa
Applications
  • Renal Anemia
  • Cancer
  • Other
Companies covered
  • Amgen
  • Cipla
  • CKD Pharma
  • Dr. Reddy's Laboratories
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Sanwa Kagaku Kenkyusho
  • Torrent Pharmaceuticals
  • Hansoh Pharma
  • Roche
  • Kyowa Kirin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting ESAs Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting ESAs Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting ESAs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting ESAs Market Dynamics
  1. 2.1 Long-acting ESAs Industry Trends
  2. 2.2 Long-acting ESAs Industry Drivers
  3. 2.3 Long-acting ESAs Industry Opportunities and Challenges
  4. 2.4 Long-acting ESAs Industry Restraints
3 Long-acting ESAs Market by Company
  1. 3.1 Global Long-acting ESAs Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting ESAs Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting ESAs Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting ESAs Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting ESAs Company Ranking (2024-2026)
  6. 3.6 Global Long-acting ESAs Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting ESAs Company Product Type and Application
  8. 3.8 Global Long-acting ESAs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting ESAs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting ESAs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting ESAs Market by Type
  1. 4.1 Long-acting ESAs Type Introduction
  2. 4.1.1 Pegmolesatide
  3. 4.1.2 Methoxy Polyethylene Glycol-Epoetin Beta
  4. 4.1.3 Darbepoetin Alfa
  5. 4.2 Global Long-acting ESAs Sales Volume by Type
  6. 4.2.1 Global Long-acting ESAs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting ESAs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Long-acting ESAs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Long-acting ESAs Sales Value by Type
  10. 4.3.1 Global Long-acting ESAs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long-acting ESAs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Long-acting ESAs Sales Value Share by Type (2021-2032)
5 Long-acting ESAs Market by Application
  1. 5.1 Long-acting ESAs Application Introduction
  2. 5.1.1 Renal Anemia
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Long-acting ESAs Sales Volume by Application
  6. 5.2.1 Global Long-acting ESAs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting ESAs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Long-acting ESAs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Long-acting ESAs Sales Value by Application
  10. 5.3.1 Global Long-acting ESAs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting ESAs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Long-acting ESAs Sales Value Share by Application (2021-2032)
6 Long-acting ESAs Regional Sales and Value Analysis
  1. 6.1 Global Long-acting ESAs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting ESAs Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting ESAs Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting ESAs Sales by Region (2027-2032)
  5. 6.3 Global Long-acting ESAs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting ESAs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting ESAs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting ESAs Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting ESAs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting ESAs Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting ESAs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting ESAs Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting ESAs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting ESAs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting ESAs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting ESAs Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting ESAs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting ESAs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting ESAs Sales Value Share by Country, 2025 VS 2032
7 Long-acting ESAs Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting ESAs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting ESAs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting ESAs Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting ESAs Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting ESAs Sales by Country (2027-2032)
  6. 7.4 Global Long-acting ESAs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting ESAs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting ESAs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting ESAs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting ESAs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting ESAs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting ESAs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting ESAs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting ESAs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting ESAs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting ESAs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting ESAs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting ESAs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting ESAs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting ESAs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting ESAs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting ESAs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting ESAs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting ESAs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting ESAs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting ESAs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting ESAs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting ESAs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting ESAs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting ESAs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting ESAs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting ESAs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting ESAs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting ESAs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting ESAs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting ESAs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting ESAs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting ESAs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Long-acting ESAs Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Cipla
  8. 8.2.1 Cipla Company Information
  9. 8.2.2 Cipla Business Overview
  10. 8.2.3 Cipla Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Long-acting ESAs Product Portfolio
  12. 8.2.5 Cipla Recent Developments
  13. 8.3 CKD Pharma
  14. 8.3.1 CKD Pharma Company Information
  15. 8.3.2 CKD Pharma Business Overview
  16. 8.3.3 CKD Pharma Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CKD Pharma Long-acting ESAs Product Portfolio
  18. 8.3.5 CKD Pharma Recent Developments
  19. 8.4 Dr. Reddy's Laboratories
  20. 8.4.1 Dr. Reddy's Laboratories Company Information
  21. 8.4.2 Dr. Reddy's Laboratories Business Overview
  22. 8.4.3 Dr. Reddy's Laboratories Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio
  24. 8.4.5 Dr. Reddy's Laboratories Recent Developments
  25. 8.5 Kissei Pharmaceutical
  26. 8.5.1 Kissei Pharmaceutical Company Information
  27. 8.5.2 Kissei Pharmaceutical Business Overview
  28. 8.5.3 Kissei Pharmaceutical Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kissei Pharmaceutical Long-acting ESAs Product Portfolio
  30. 8.5.5 Kissei Pharmaceutical Recent Developments
  31. 8.6 Kyowa Hakko Kirin
  32. 8.6.1 Kyowa Hakko Kirin Company Information
  33. 8.6.2 Kyowa Hakko Kirin Business Overview
  34. 8.6.3 Kyowa Hakko Kirin Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kyowa Hakko Kirin Long-acting ESAs Product Portfolio
  36. 8.6.5 Kyowa Hakko Kirin Recent Developments
  37. 8.7 Sanwa Kagaku Kenkyusho
  38. 8.7.1 Sanwa Kagaku Kenkyusho Company Information
  39. 8.7.2 Sanwa Kagaku Kenkyusho Business Overview
  40. 8.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio
  42. 8.7.5 Sanwa Kagaku Kenkyusho Recent Developments
  43. 8.8 Torrent Pharmaceuticals
  44. 8.8.1 Torrent Pharmaceuticals Company Information
  45. 8.8.2 Torrent Pharmaceuticals Business Overview
  46. 8.8.3 Torrent Pharmaceuticals Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Torrent Pharmaceuticals Long-acting ESAs Product Portfolio
  48. 8.8.5 Torrent Pharmaceuticals Recent Developments
  49. 8.9 Hansoh Pharma
  50. 8.9.1 Hansoh Pharma Company Information
  51. 8.9.2 Hansoh Pharma Business Overview
  52. 8.9.3 Hansoh Pharma Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hansoh Pharma Long-acting ESAs Product Portfolio
  54. 8.9.5 Hansoh Pharma Recent Developments
  55. 8.10 Roche
  56. 8.10.1 Roche Company Information
  57. 8.10.2 Roche Business Overview
  58. 8.10.3 Roche Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Roche Long-acting ESAs Product Portfolio
  60. 8.10.5 Roche Recent Developments
  61. 8.11 Kyowa Kirin
  62. 8.11.1 Kyowa Kirin Company Information
  63. 8.11.2 Kyowa Kirin Business Overview
  64. 8.11.3 Kyowa Kirin Long-acting ESAs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Kyowa Kirin Long-acting ESAs Product Portfolio
  66. 8.11.5 Kyowa Kirin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting ESAs Value Chain Analysis
  2. 9.1.1 Long-acting ESAs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting ESAs Sales Mode & Process
  6. 9.2 Long-acting ESAs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting ESAs Distributors
  9. 9.2.3 Long-acting ESAs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst